Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study

Inclusion Criteria:

• 18-65 years old, no gender limit;
• ECOG 0-2, estimated survival time ≥ 3 months;
• Pathologically newly diagnosed with PTCL (except ALK+ anaplastic large cell lymphoma),with PR or CR after 6 cycles of induction chemotherapy;
• Hb≥80g/L, ANC≥1.0×10^9/L, PLT≥75×10^9/L; TBIL≤1.5×ULN, ALT/AST≤2.0× ULN, Cr ≤1.5×ULNin the 14 days before enrollment
• Have not received hematopoietic stem cell transplantation and other treatments within 4 weeks before enrollment;
• The number of hematopoietic stem cells requires MNC ≥3×10^8/kg and/or CD34 cells ≥2×10^6/kg;
• Informed consented

Exclusion Criteria:

• Accompanied by severe cardiac insufficiency, cardiac ejection fraction <60%; or severearrhythmia, intolerance of pretreatment;
• Accompanied by severe pulmonary insufficiency (obstructive and or restrictiveventilatory disorders), intolerance of pretreatment;
• Accompanied by severe liver function impairment, liver function indexes (ALT, TBIL)are more than 3 times higher than the upper limit of normal, intolerance ofpretreatment;
• Accompanied by severe renal insufficiency, the renal function index (Cr) is more than 2 times the upper limit of normal; or the 24-hour urine creatinine clearance rate Ccris less than 50ml/min, intolerance of pretreatment;
• Severe active infection before transplantation, intolerance of pretreatment;
• Accompanied by brain dysfunction or severe mental illness, unable to understand orfollow the research plan;
• Pregnant or lactation；
• Accompanied by other malignant tumors in need of treatment;
• Patients who cannot guarantee the completion of the necessary treatment plan andfollow-up observation.